Protocols

How Do the FDA's June 2026 Enforcement Actions Against Unapproved Semaglutide, Tirzepatide, and Retatrutide Change Dosing and Safety Protocols?

June 30, 2026 · 10 min read · Research Stage

How Do the FDA's June 2026 Enforcement Actions Against Unapproved Semaglutide, Tirzepatide, and Retatrutide Change Dosing and Safety Protocols?

The FDA's June 2026 wave of 25 warning letters to telehealth companies — combined with its standing position that retatrutide cannot be legally compounded — materially narrows the landscape for practitioners using GLP-1 peptide protocols. Compounded semaglutide and tirzepatide now face tighter sourcing requirements, while retatrutide products outside clinical trials carry no regulatory pathway whatsoever.

What Specifically Triggered the June 2026 Enforcement Wave?

The June 2026 letters — the third major enforcement round after roughly 80 letters in September 2025 and 30 in March 2026 — targeted telehealth companies making false or misleading promotional claims about compounded GLP-1 products. Primary violations included implying equivalence with FDA-approved branded formulations and obscuring the compounded origin of the products being dispensed.

The FDA's escalating enforcement timeline reflects a deliberate ratcheting strategy. The agency removed semaglutide and tirzepatide from its drug shortage list in early 2025, which legally extinguished the shortage-based exemption that had permitted large-scale 503B outsourcing facility compounding. The June 2026 letters did not introduce new legal prohibitions; instead, they applied existing misbranding and false-claims statutes to promotional materials that persisted after prior warnings.

The Sheppard Mullin regulatory analysis of the June 2026 letters noted that the letters were "highly standardized," suggesting the FDA is building a documented enforcement record rather than negotiating case-by-case. That pattern has direct implications for practitioners: sourcing from any entity that received a warning letter introduces compounding liability risk into a clinical protocol.

Why Is Retatrutide in a Categorically Different Regulatory Position?

Retatrutide is not FDA-approved and has no commercially available reference product. The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law — unlike semaglutide and tirzepatide, which had a narrow shortage-based compounding window. Any product sold as retatrutide outside an active clinical trial is an unapproved new drug with no legal compounding pathway.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Its Phase 2 data, published in The New England Journal of Medicine in 2023, showed mean weight loss of approximately 24% at 48 weeks in the highest-dose cohort. That figure generated substantial consumer demand before Phase 3 trials were complete, which is precisely what drove illicit compounding activity.

Because no reference standard exists for retatrutide's active pharmaceutical ingredient outside Eli Lilly's proprietary synthesis, compounders cannot demonstrate that their material is the same molecule at the same purity. The peptide sequence, salt form, and impurity profile of circulating "retatrutide" products are unverifiable by any currently available third-party testing framework.

What Is the Salt-Form Problem With Compounded Semaglutide?

FDA-approved semaglutide uses the base form of the molecule. Many compounded products have used semaglutide acetate or semaglutide sodium — salt forms the FDA explicitly states are different active ingredients, not equivalent substitutes. Using a salt form means the pharmacokinetic and pharmacodynamic profile of the compounded product is not established by the clinical trial data for the approved drug.

The salt-form distinction is mechanistically significant. Semaglutide's half-life of approximately 165–184 hours in the approved formulation depends on its albumin-binding fatty acid side chain and the specific molecular configuration of the base form. A salt form alters the ionization state of the molecule, which can affect solubility, absorption kinetics, and receptor binding affinity.

The magnitude of these pharmacokinetic differences in vivo has not been formally characterized for the acetate or sodium variants. Practitioners titrating patients on compounded semaglutide using dose escalation schedules derived from the SUSTAIN or STEP trial data are therefore working with an assumption of pharmacokinetic equivalence that the FDA explicitly rejects. If the salt form delivers a different exposure curve, the standard titration schedule may not provide the intended safety margin.

What Adverse Events Have Been Linked to Compounded GLP-1 Dosing Errors?

The FDA's MedWatch database and its July 2024 safety alert documented adverse events from compounded semaglutide including severe nausea, vomiting, abdominal pain, fainting, and headache — several requiring hospitalization. The primary driver was dosing errors arising from concentration variability in compounded vials and unit-conversion confusion between milligrams and units on multi-dose pens.

Concentration variability is a structural problem in compounded injectables. Unlike a prefilled pen with a fixed dose-per-click mechanism, compounded semaglutide is typically supplied in multi-dose vials requiring the patient or practitioner to draw and measure each dose. Errors in this process are well-documented in insulin compounding literature and translate directly to GLP-1 peptides.

A tenfold dosing error — drawing 1 mL instead of 0.1 mL from a 1 mg/mL solution — is a plausible user error with serious consequences. The 2026 PMC review (PMC12164287) on global compounded weight-loss medicines noted that compounded drugs carry greater risk than FDA-approved drugs due to reduced oversight and the absence of clinical testing for the specific formulation.

How Do 503A and 503B Distinctions Affect Current Protocol Viability?

Under the Drug Quality and Security Act, 503A pharmacies may still compound semaglutide or tirzepatide for individual patients under narrow exceptions — such as documented excipient allergies or a required dose strength not commercially available. 503B outsourcing facilities lost their shortage-based exemption when GLP-1s were removed from the shortage list and cannot legally compound essentially equivalent copies of approved drugs.

The practical implication for protocol design is that 503A compounding remains a legal pathway in specific, documented clinical circumstances — but the documentation burden has increased substantially. A practitioner relying on 503A-compounded semaglutide must demonstrate a patient-specific medical necessity that the approved product cannot fulfill. Convenience, cost, and dose flexibility are not qualifying justifications under the current regulatory framework.

503B facilities that continued compounding after the shortage designation ended face the most acute enforcement risk. The June 2026 warning letters targeted the promotional layer of telehealth companies, but underlying supply-chain enforcement against 503B facilities has been ongoing since early 2025. Practitioners sourcing from 503B facilities should verify current compliance status before continuing any active protocol.

What Specific Safety Protocol Adjustments Are Now Warranted?

Practitioners managing patients on GLP-1 peptide protocols should now implement four evidence-driven adjustments: verify the compounding source's 503A status and warning-letter history; confirm the active ingredient is semaglutide base rather than a salt form; use standardized concentration vials with pre-marked syringes to eliminate unit-conversion errors; and establish a documented adverse-event monitoring plan aligned with the FDA's MedWatch framework.

Titration schedule integrity is the most immediately actionable safety lever. The standard semaglutide titration was designed around the pharmacokinetics of the approved base-form product. If a compounded product's actual concentration or salt form deviates from the label, the titration schedule loses its calibration.

Verifying concentration by requesting a certificate of analysis from the compounding pharmacy is a minimum standard, not an optional precaution. For tirzepatide protocols, the dual GIP/GLP-1 agonism creates a more complex adverse-event profile than semaglutide alone.

The approved Mounjaro titration begins at 2.5 mg weekly and escalates in 2.5 mg increments at four-week intervals. Compounded tirzepatide with uncertain purity introduces the same concentration-error risks as semaglutide, with the additional variable of GIP receptor engagement that has not been characterized for non-reference formulations.

What Documentation Should Practitioners Maintain Under the 2026 Regulatory Environment?

Under the current enforcement climate, practitioners prescribing compounded GLP-1 peptides should maintain records demonstrating: the patient-specific medical necessity justifying compounding over the approved product; the compounding pharmacy's 503A registration and compliance status; the certificate of analysis for each dispensed lot; and a signed informed-consent document explicitly disclosing the unapproved status of the compounded formulation.

The FDA's warning letters to telehealth companies specifically cited failure to disclose the compounded — and therefore unapproved — nature of the products being marketed. That disclosure obligation extends to the prescribing practitioner's informed-consent process. A patient who believes they are receiving the same product as Ozempic or Mounjaro has not provided meaningful informed consent for a compounded formulation with a different regulatory status and unverified bioequivalence.

Adverse event reporting through MedWatch is not optional when a practitioner observes a serious adverse event associated with a compounded product. The FDA's ability to build the evidence base that drives future enforcement depends on systematic reporting. Practitioners who observe hospitalization-level events associated with compounded GLP-1 dosing errors have both an ethical and a regulatory obligation to report.

Safety Considerations for Patients Currently on Compounded GLP-1 Protocols

Patients currently using compounded semaglutide or tirzepatide should not abruptly discontinue without practitioner guidance, as GLP-1 receptor agonist withdrawal can cause rapid weight regain and metabolic rebound. The appropriate response to regulatory uncertainty is a structured transition plan — either to an FDA-approved formulation or to a verified 503A-compounded product — not unilateral discontinuation.

Patients using any product labeled as retatrutide outside a registered clinical trial should be counseled that there is no legal compounding pathway for this compound, no reference standard for purity verification, and no clinical safety data for the specific formulations in circulation. The Phase 2 trial data for retatrutide was generated under tightly controlled pharmaceutical manufacturing conditions that no compounding pharmacy can replicate.

Gastrointestinal adverse effects — nausea, vomiting, diarrhea, and constipation — are the most common class effects of GLP-1 receptor agonists at any dose. When these occur with compounded products, the differential includes both expected pharmacological effects and concentration-error overdose. Practitioners should have a structured protocol for distinguishing expected titration-phase GI effects from overdose signals, including a threshold for dose reduction or temporary discontinuation. What Does the 2026 Clinical Evidence Actually Show for BPC-157 in Shoulder Rotator Cuff Tears? How Do You Cycle GH Peptides Without Crashing Endogenous Production in 2026? What Does 2026 Research Reveal About BPC-157 for Musculoskeletal Healing — Regeneration or Risk?

Frequently Asked Questions

The June 2026 letters — the third major enforcement round after roughly 80 letters in September 2025 and 30 in March 2026 — targeted telehealth companies making false or misleading promotional claims about compounded GLP-1 products. Primary violations included implying equivalence with FDA-approved branded formulations and obscuring the compounded origin of the products being dispensed.

Retatrutide is not FDA-approved and has no commercially available reference product. The FDA has explicitly stated it cannot be used in compounding under federal law. Any product sold as retatrutide outside an active clinical trial is an unapproved new drug with no legal compounding pathway — unlike semaglutide and tirzepatide, which had a narrow shortage-based compounding window.

FDA-approved semaglutide uses the base form of the molecule. Many compounded products have used semaglutide acetate or semaglutide sodium — salt forms the FDA explicitly states are different active ingredients. Using a salt form means the pharmacokinetic and pharmacodynamic profile is not established by the clinical trial data for the approved drug, potentially invalidating standard titration schedules.

The FDA's MedWatch database and July 2024 safety alert documented severe nausea, vomiting, abdominal pain, fainting, and headache — several requiring hospitalization. The primary driver was dosing errors from concentration variability in compounded vials and unit-conversion confusion between milligrams and units on multi-dose pens.

Yes, under narrow exceptions — such as documented excipient allergies or a required dose strength not commercially available. However, 503B outsourcing facilities lost their shortage-based exemption when GLP-1s were removed from the shortage list and cannot legally compound essentially equivalent copies of approved drugs.

Practitioners should verify the compounding source's 503A status and warning-letter history; confirm the active ingredient is semaglutide base rather than a salt form; use standardized concentration vials with pre-marked syringes to eliminate unit-conversion errors; and establish a documented adverse-event monitoring plan aligned with the FDA's MedWatch framework.

Records should demonstrate patient-specific medical necessity justifying compounding over the approved product; the compounding pharmacy's 503A registration and compliance status; the certificate of analysis for each dispensed lot; and a signed informed-consent document explicitly disclosing the unapproved status of the compounded formulation.

No. Abrupt discontinuation can cause rapid weight regain and metabolic rebound. The appropriate response is a structured transition plan — either to an FDA-approved formulation or to a verified 503A-compounded product with confirmed ingredient form and concentration — managed in consultation with a practitioner.

Sources

  1. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
  2. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
  3. U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products
  4. U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
  5. Sheppard Mullin Richter & Hampton LLP. FDA's Focus Returns to Compounding and Telehealth — Another Wave of Warning Letters
  6. PMC / National Institutes of Health. Global Rise of Compounded Weight-Loss Medicines
  7. PMC / National Institutes of Health. Adverse Events Administering Glucagon-Like Peptide-1 Receptor Agonists
  8. U.S. Food and Drug Administration. FDA Telehealth Companies: What to Know When Promoting Compounded Drugs
  9. Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s
  10. Nature Metabolism. The Incretin Co-Agonist Tirzepatide Requires GIPR for Hormone Secretion
Peptides Plus editorial — evidence-based protocol summaries, no commercial affiliations. Consult a qualified healthcare provider before beginning any peptide protocol.